交易 ARCA Biopharma - ABIO CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|
ARCA Biopharma Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Monday, July 31, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家/地区 US
| 事件 Q2 2023 ARCA Biopharma Inc Earnings Release Q2 2023 ARCA Biopharma Inc Earnings ReleaseForecast -Previous - |
Thursday, October 26, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家/地区 US
| 事件 Q3 2023 ARCA Biopharma Inc Earnings Release Q3 2023 ARCA Biopharma Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 10.596 | 19.335 | 9.766 | 5.814 | 8.118 |
销售/一般/行政费用,总计 | 5.847 | 5.503 | 4.774 | 3.981 | 3.879 |
研究与开发 | 4.749 | 13.832 | 4.992 | 1.833 | 4.239 |
营业收入 | -10.596 | -19.335 | -9.766 | -5.814 | -8.118 |
利息收入(费用),非经营净值 | 0.675 | 0.013 | 0.019 | 0.165 | 0.154 |
税前净收入 | -9.926 | -19.322 | -9.747 | -5.649 | -7.964 |
税后净收入 | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
未计算非常项目前的净收益 | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
净收入 | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
普通股股东可获收益 (不含非经常性项目) | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
普通股股东可获收益 (含非經常性項目) | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
摊薄净收入 | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
摊薄后加权平均股 | 14.4101 | 13.9039 | 4.71024 | 1.32123 | 0.76939 |
扣除特别项目的每股摊薄盈利 | -0.68882 | -1.38968 | -2.06741 | -4.14915 | -10.3107 |
每股正常摊薄盈利 | -0.68882 | -1.38968 | -2.06741 | -4.14915 | -10.3107 |
其他,净值 | -0.005 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 1.796 | 1.548 | 2.552 | 3.219 | 3.277 |
销售/一般/行政费用,总计 | 1.406 | 1.487 | 1.528 | 1.734 | 1.098 |
研究与开发 | 0.39 | 0.061 | 1.024 | 1.485 | 2.179 |
营业收入 | -1.796 | -1.548 | -2.552 | -3.219 | -3.277 |
利息收入(费用),非经营净值 | 0.45 | 0.374 | 0.222 | 0.072 | 0.007 |
税前净收入 | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
税后净收入 | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
未计算非常项目前的净收益 | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
净收入 | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
普通股股东可获收益 (不含非经常性项目) | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
普通股股东可获收益 (含非經常性項目) | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
摊薄净收入 | -1.346 | -1.174 | -2.333 | -3.147 | -3.272 |
摊薄后加权平均股 | 14.4101 | 14.4101 | 14.4101 | 14.4101 | 14.4101 |
扣除特别项目的每股摊薄盈利 | -0.09341 | -0.08147 | -0.1619 | -0.21839 | -0.22706 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.09341 | -0.08147 | -0.1619 | -0.21839 | -0.22706 |
其他,净值 | 0 | 0 | -0.003 | 0 | -0.002 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 42.699 | 54.421 | 49.968 | 8.48 | 6.777 |
现金和短期投资 | 42.445 | 53.359 | 49.071 | 8.363 | 6.608 |
现金等价物 | 42.445 | 53.359 | 49.071 | 8.363 | 6.608 |
短期投资 | 0 | ||||
Other Current Assets, Total | 0.254 | 1.062 | 0.897 | 0.117 | 0.169 |
Total Assets | 43.085 | 54.924 | 50.429 | 8.536 | 6.825 |
Property/Plant/Equipment, Total - Net | 0.368 | 0.485 | 0.449 | 0.032 | 0.024 |
Property/Plant/Equipment, Total - Gross | 0.572 | 0.68 | 0.699 | 0.399 | 0.398 |
Accumulated Depreciation, Total | -0.204 | -0.195 | -0.25 | -0.367 | -0.374 |
Long Term Investments | |||||
Other Long Term Assets, Total | 0.018 | 0.018 | 0.012 | 0.024 | 0.024 |
Total Current Liabilities | 1.132 | 3.498 | 3.499 | 0.926 | 0.793 |
Accounts Payable | 0.334 | 1.117 | 1.773 | 0.418 | 0.23 |
Accrued Expenses | 0.798 | 2.381 | 1.726 | 0.508 | 0.563 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.412 | 3.881 | 3.908 | 0.926 | 0.793 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.28 | 0.383 | 0.409 | 0 | |
Total Equity | 41.673 | 51.043 | 46.521 | 7.61 | 6.032 |
Common Stock | 0.014 | 0.014 | 0.01 | 0.002 | 0.014 |
Additional Paid-In Capital | 225.061 | 224.505 | 200.665 | 152.024 | 144.952 |
Retained Earnings (Accumulated Deficit) | -183.402 | -173.476 | -154.154 | -144.416 | -138.934 |
Other Equity, Total | |||||
Total Liabilities & Shareholders’ Equity | 43.085 | 54.924 | 50.429 | 8.536 | 6.825 |
Total Common Shares Outstanding | 14.4101 | 14.4101 | 9.54815 | 1.59407 | 0.77356 |
Preferred Stock - Non Redeemable, Net | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 41.702 | 42.699 | 44.55 | 47.655 | 50.539 |
现金和短期投资 | 40.85 | 42.445 | 43.939 | 46.437 | 49.059 |
现金等价物 | 40.85 | 42.445 | 43.939 | 46.437 | 49.059 |
Other Current Assets, Total | 0.852 | 0.254 | 0.611 | 1.218 | 1.48 |
Total Assets | 42.059 | 43.085 | 44.965 | 48.101 | 51.014 |
Property/Plant/Equipment, Total - Net | 0.339 | 0.368 | 0.397 | 0.428 | 0.457 |
Property/Plant/Equipment, Total - Gross | 0.547 | 0.572 | 0.598 | 0.632 | 0.655 |
Accumulated Depreciation, Total | -0.208 | -0.204 | -0.201 | -0.204 | -0.198 |
Other Long Term Assets, Total | 0.018 | 0.018 | 0.018 | 0.018 | 0.018 |
Total Current Liabilities | 1.266 | 1.132 | 1.937 | 2.809 | 2.719 |
Accounts Payable | 0.366 | 0.334 | 0.593 | 1.11 | 1.014 |
Accrued Expenses | 0.9 | 0.798 | 1.344 | 1.699 | 1.705 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.528 | 1.412 | 2.238 | 3.138 | 3.076 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.262 | 0.28 | 0.301 | 0.329 | 0.357 |
Total Equity | 40.531 | 41.673 | 42.727 | 44.963 | 47.938 |
Common Stock | 0.014 | 0.014 | 0.014 | 0.014 | 0.014 |
Additional Paid-In Capital | 225.265 | 225.061 | 224.941 | 224.844 | 224.672 |
Retained Earnings (Accumulated Deficit) | -184.748 | -183.402 | -182.228 | -179.895 | -176.748 |
Total Liabilities & Shareholders’ Equity | 42.059 | 43.085 | 44.965 | 48.101 | 51.014 |
Total Common Shares Outstanding | 14.4101 | 14.4101 | 14.4101 | 14.4101 | 14.4101 |
Preferred Stock - Non Redeemable, Net | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
经营活动产生的现金 | -10.912 | -18.762 | -7.725 | -4.801 | -8.244 |
经营活动产生的现金 | 0.02 | 0.016 | 0.008 | 0.018 | 0.022 |
非现金物品 | 0.655 | 0.572 | 0.128 | 0.222 | 0.275 |
已付现金利息 | 0 | 0 | 0.009 | 0.007 | 0.008 |
营运资金的变化 | -1.661 | -0.028 | 1.877 | 0.441 | -0.608 |
投资活动产生的现金 | -0.002 | -0.043 | -0.019 | -0.004 | 3.046 |
资本支出 | -0.002 | -0.043 | -0.019 | -0.004 | -0.004 |
其他投资现金流量项目,总计 | 0 | 3.05 | |||
融资活动产生的现金 | 0 | 23.093 | 48.452 | 6.56 | 3.104 |
融资现金流项目 | 0 | -0.977 | -2.034 | -0.372 | -0.117 |
股票的发行(报废),净额 | 0 | 24.07 | 50.894 | 7.281 | 3.532 |
债务的发行(退还),净额 | 0 | -0.408 | -0.349 | -0.311 | |
现金净变化 | -10.914 | 4.288 | 40.708 | 1.755 | -2.094 |
Cash Taxes Paid | 0 | 0 | 0.009 | -0.167 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -1.346 | -9.926 | -8.752 | -6.419 | -3.272 |
Cash From Operating Activities | -1.595 | -10.912 | -9.418 | -6.92 | -4.298 |
Cash From Operating Activities | 0.004 | 0.02 | 0.015 | 0.011 | 0.005 |
Non-Cash Items | 0.229 | 0.655 | 0.511 | 0.387 | 0.192 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0 | 0 | 0 | 0 | 0 |
Changes in Working Capital | -0.482 | -1.661 | -1.192 | -0.899 | -1.223 |
Cash From Investing Activities | 0 | -0.002 | -0.002 | -0.002 | -0.002 |
Capital Expenditures | 0 | -0.002 | -0.002 | -0.002 | -0.002 |
Cash From Financing Activities | 0 | 0 | 0 | 0 | 0 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -1.595 | -10.914 | -9.42 | -6.922 | -4.3 |
Issuance (Retirement) of Debt, Net |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Cable Car Capital LLC | Investment Advisor/Hedge Fund | 27.7614 | 4000452 | 0 | 2023-02-15 | HIGH |
BML Capital Management LLC | Investment Advisor | 4.9058 | 706930 | -151326 | 2023-03-31 | MED |
Newtyn Management, LLC | Hedge Fund | 3.6069 | 519765 | -18513 | 2023-03-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.2422 | 467205 | 7800 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.8185 | 262046 | 1050 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.08 | 155635 | 0 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.4971 | 71637 | 0 | 2023-03-31 | LOW |
Murchinson Ltd. | Investment Advisor/Hedge Fund | 0.3664 | 52800 | 2207 | 2023-03-31 | LOW |
Ozeroff (Christopher David) | Individual Investor | 0.3537 | 50970 | 0 | 2023-02-15 | LOW |
Conway (Robert E) | Individual Investor | 0.347 | 50000 | 0 | 2023-02-15 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3258 | 46948 | 0 | 2023-03-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.2949 | 42502 | 0 | 2023-03-31 | LOW |
Dekker (C Jeffrey) | Individual Investor | 0.2776 | 40000 | 40000 | 2022-12-08 | |
Renaissance Technologies LLC | Hedge Fund | 0.2755 | 39700 | 4500 | 2023-03-31 | HIGH |
Tekla Capital Management LLC | Investment Advisor | 0.2253 | 32461 | 0 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.175 | 25211 | 19730 | 2023-03-31 | HIGH |
Group One Trading, L.P. | Research Firm | 0.1596 | 23000 | 23000 | 2023-03-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1456 | 20982 | 3465 | 2023-03-31 | LOW |
Marquette Wealth Management | Investment Advisor | 0.1202 | 17318 | 0 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.104 | 14988 | 14988 | 2023-03-31 | LOW |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投资
交易规模(杠杆 x 投资):
開倉
平仓
做空 做多
ARCA Biopharma Company profile
关于 ARCA Biopharma
ARCA生物制药公司(ARCA)是一家生物制药公司。 公司专注于心血管疾病靶向疗法的开发和商业化。 公司的主导产品包括重组线虫抗凝血蛋白c2,或rNAPc2(AB201)和Gencaro(盐酸布心洛尔)。rNAPc2(AB201)是治疗由核糖核酸(RNA)、病毒引起的疾病,重点是COVID-19,即由SARS-CoV-2病毒引起的疾病综合症。 Gencaro(bucindolol hydrochloride)是一种药物基因靶向的β-肾上腺素能受体拮抗剂,具有温和的血管扩张特性,用于治疗心力衰竭患者的心房颤动(AF)。 房颤是心律失常的一种形式,是心脏正常节律或速率的破坏。 公司正在进行rNAPc2(AB201)的II期b临床试验,ASPEN-COVID-19。 它还在进行Gencaro的IIB/III期临床试验。
Industry: | Bio Therapeutic Drugs |
Suite 430
8001 Arista Place
BROOMFIELD
COLORADO 80021
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。